Abstract: The present invention relates to nutritional composition for infants and/or children comprising lactoferrin and probiotics. These compositions have been found to be useful in providing health benefits in infants and/or children. A method of manufacture of these compositions is also part of the invention. These compositions may be in the form of a kit of parts wherein a first composition according to the invention and a second composition according to the invention are each adapted to fulfil the nutritional requirements in two different age groups.

Abstract: The invention relates to a composition comprising an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527, Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529, These new strains have good probiotic features and are useful for the prevention and/or the treatment of cardiovascular disorders.

Abstract: The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.

Abstract: Provided is an agent or a food or drink for reducing the risk of developing breast cancer. An agent for reducing the risk of developing breast cancer which comprises a composition containing living cells of Lactobacillus casei.

Abstract: Improved compositions and methods are disclosed for improving food safety. More specifically, one or more lactic acid producing microorganisms are used for inhibiting pathogenic growth on plant materials before, during and/or after harvest. The disclosed methodology is particularly effective for leafy vegetables, such as spinach.

Abstract: The present invention relates to a probiotic preparation for preventing and treating canine gastrointestinal disorders containing at least two dog-specific strains of lactic acid bacteria belonging to genus Lactobacillus, a calcium source in an amount of 20-99 weight-% expressed as CaCO3 of the dry weight of the preparation, and at least one prebiotic, and optionally additional dog-specific strains of lactic acid bacteria, excipients and carriers. The invention further relates to a process for the manufacture of the probiotic preparation, to dog food comprising the probiotic preparation, and to the use of the probiotic preparation for the manufacture of a pharmaceutical product or a dog food product for preventing and treating canine gastrointestinal disorders.

Abstract: The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to a composition comprising probiotics consisting of Lactobacillus rhamnosus LC70 alone or Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC705. Also the invention relates to the composition for use as a medicament. Furthermore, the present invention relates to uses of Lactobacillus rhamnosus LC705 alone or together with Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection and for intensifying resistance against viruses causing respiratory infections in a subject. Furthermore, the present invention describes uses of Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection in an adult and for intensifying resistance against viruses causing respiratory infections in an adult subject.

Abstract: The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase (lactose-phlorizin hydrolase or LPH). This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria show improved ability to digest lactose in dairy foods.

Abstract: Nutritional compositions including fiber blends having a stable amount of probiotics and methods of making the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a fiber blend having agglomerated fiber particulates and a probiotic. The fiber blend can have a water activity of less than about 0.15. The nutritional composition can be in an administerable form such as pharmaceutical formulations, nutritional formulations, dietary supplements, functional foods and beverage products.

Abstract: The present invention relates to the field of enteral nutrition to be administered via tube feeding. In particular, the present invention provides tube feeding modules comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example.

Abstract: The present invention relates to a medicament for oral administration containing at least one estrogen and/or one gestagen and at least one probiotic bacterial strain, such as for example lactobacillus species. The medicament according to the invention is used either for oral contraception or for hormone therapy (HT), during which it can simultaneously serve for the stabilization of the vaginal environment and hence the prevention of infectious diseases, such as for example vaginal mycosis, bacterial vaginosis and/or bladder inflammation (bacterial cystitis) or the prevention of urogenital symptoms, e.g. dyspareunia and dysuria. The present invention further relates to pharmaceutical combination preparations which contain dosage units containing an aforesaid medicament and further dosage units containing exclusively a probiotic bacterial strain.

Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including one or more exogenous nucleotides.

Abstract: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics.

Abstract: Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This presents a theoretical risk of a horizontal transfer of functional antibiotic genes. The present invention relates to novel tetracycline-sensitive strains of the well-known probiotic Bifidobacterium animalis subsp. lactis strain BB-12® and the use of such novel strains for the preparation of a food or feed product or a dosage form comprising viable organisms.

Abstract: The present invention provides Lactobacillus bacteria which enhance the functional of Peyer's patch and promote IgA production and which have a characteristics of localizing on human intestine as well as an agent for promoting IgA production. The present invention is directed to an agent for promoting IgA production containing Lactobacillus amylovorus cells, especially Lactobacillus amylovorus CP1750 (FERM BP-10532) as an active ingredient.

Abstract: The present invention relates to the field of nutrition. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics.

Abstract: Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided.

Abstract: The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms.

Abstract: A use of probiotic strain GM-263 (ADR-1) in treating renal fibrosis in diabetes is disclosed. The probiotic strain such as Lactobacillus renteri strain GM-263 (ADR-1) (accession No. CCTCC M 209263) is utilized to produce a composition for treating renal fibrosis in diabetes in an effective dose, thereby reducing the concentration of glycated hemoglobin and blood sugar and keeping body weight and kidney weight within normal range, as well as specifically inhibiting phosphorylation of JAK2/STAT1 signal transduction pathway and renal fibrosis-related protein expression.

Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

Abstract: Lactobacillus strains that have a genetic Profile I based on Apa I, Not I, and Xba I digests are provided. Preferably, the strains decrease level of at least one of coliforms and E. coli within the gastrointestinal tract of an animal. A direct-fed microbial that includes the strain is additionally provided. A method of feeding an animal the strain and a method of forming a direct fed microbial that includes the strain is also provided.

Abstract: A novel strain of Lactobacillus fermentum, denoted strain Ess-1, which has been deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH and has been assigned accession number DSM17851. Lactobacillus fermentum, strain Ess-1, has shown valuable properties in the inhibition of Candida, and has medical uses, in particular for the treatment and/or prevention of candidasis and urinary tract infections. In addition, pharmaceutical products and articles include the novel bacterial strain.

Abstract: The present invention relates to a method of reducing the acid concentration within gastric fluid, suppressing a tendency towards a strongly acidic pH within the gastric fluid, and inhibiting the production of gastrin, by administering lived or killed lactic acid bacterium (such as Lactobacillus johnsonii No. 1088) to a living subject. The invention also relates to a method of alleviating the side effects caused by continuous administration of a proton pump inhibitor by administering lived or killed lactic acid bacterium to a living subject.

Abstract: A method for inhibiting a bacterial invasive mechanism involving administering to a human a nutritional composition including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide; at least about 10 mg/100 kCal of lactoferrin selected from the group consisting of non-human lactoferrin, human lactoferrin produced by a genetically modified organism, and combinations thereof.

Abstract: The present invention relates to a nutritional composition, in particular directed to toddlers and/or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises iron, zinc, vitamin D and/or sialic acid. Preferably, the composition comprises a source of phospholipids rich in DHA.

Abstract: A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source.

Abstract: The present invention relates to a nutritional composition, in particular directed to children of 3-6 years, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid) and/or ARA (arachidonic acid). The nutritional composition improves cognitive performance, in particular memory, learning comprehension, alertness, attention, concentration, processing speed, conceptual thinking, abstract thinking, verbal abilities, language comprehension, psychomotor skills, curiosity, and confident interaction with the environment. Preferably, the composition comprises one, a combination of several or all selected of the group of DHA, ARA, LA, ALA, choline, iron, iodine and folic acid.

Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.

Abstract: The present invention relates to a selected strain of Lactobacillus pentosus for use as a medication for the preventive or curative treatment of infections due to Gram-negative bacteria, preferably enterococci, coliforms and E. coli.

Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the preventional and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.

Abstract: The present invention generally relates to the field of bacteria. In particular, the present invention concerns “short time high temperature” treated probiotics and/or dairy starter cultures and applications of these bacteria. One embodiment of the present invention relates to “short-time high temperature” treated probiotics and/or dairy starter cultures and their use to prepare compositions to treat or prevent inflammatory disorders.

Abstract: The invention pertains to a composition for stimulating muscle strength in elderly, comprising whey protein, free BCAA and probiotic bacteria, wherein the composition comprises one or more free BCAAs selected from the group consisting of leucine, isoleucine and valine, and at least 50 g whey protein per 100 g dry weight of the total composition. Also, the invention pertains to a composition additionally comprising one or more dietary fibers selected from the group of pectins, pectates, alginates, fructans, fructooligosaccharides, indigestible dextrins, galactooligosaccharides, xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligosaccharides and fucooligosaccharides, and to the use of such composition in dietary management of malnutrition of elderly.

Abstract: The present invention relates to the field of enteral nutrition to be administered via tube feeding. In particular, the present invention provides tube feeding formulas for complete nutrition comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example.

Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.

Abstract: The present invention relates to use of a probiotic to normalize abnormal inflammation markers. The present invention also relates to use of a probiotic for preventing and/or treating low-grade inflammation. Further, the present invention relates to use of a probiotic for preventing and/or treating disorders and/or diseases relating to low-grade inflammation.

Abstract: The present invention relates to the fields of hydration and nutrition for dysphagic patients. In particular, the present invention relates to thickeners comprising probiotic microorganisms and to compositions comprising such thickeners. The probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic microorganisms.

Abstract: The present invention relates to a process for stabilizing aqueous preparations of minerals by adding reuterin to the aqueous preparations, to the use of reuterin for the stabilization of such aqueous mineral preparations, and the aqueous mineral preparations containing reuterin.

Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.

Abstract: The invention provides methods for treating respiratory infections by administering compositions comprising one or more isolated, non-pathogenic, hydrogen peroxide-producing bacterial species or strains to the mouth, oropharynx, larynx, nasal cavity, fauces of a subject.

Abstract: To provide a novel lactic acid bacterium strain having a broad antibacterial spectrum against bacteria that cause oral diseases, from which a fermented product having good flavor and being excellent in palatability can be produced, and a prophylactic, ameliorating or therapeutic agent for oral diseases using the same. A prophylactic, ameliorating or therapeutic agent for an oral disease, which contains a lactic acid bacterial cell of one or more kinds selected from the group consisting of Lactobacillus rhamnosus strain KO3, Lactobacillus casei strain YU3 and Lactobacillus paracasei strain YU4 or a culture of the cell, or an extract thereof, as an active ingredient.

Abstract: The present invention relates to the field of infant nutrition. In particular, the present invention relates to infant feeding formulas comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Abstract: The present invention provides a tea-based fermentation beverage comprising a tea-based fermentation liquid with at least one species of lactic acid bacteria selected from the group consisting of Lactobacillus ONRIC b0239 (FERM BP-10064) and Lactobacillus ONRIC b0240 (FERM BP-10065), and a tea beverage comprising at least one species of lactic acid bacteria selected from the group consisting of Lactobacillus ONRIC b0239 (FERM BP-10064) and Lactobacillus ONRIC b0240 (FERM BP-10065).

Abstract: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the nutritional compositions intended for children with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to children with an impaired function of the gastrointestinal tract comprising probiotic micro-organisms. The probiotic micro-organisms may be non-replicating, for example bioactive heat treated probiotic micro-organisms.

Abstract: The present invention relates to the field of nutrition for adults. In particular, the present invention relates to the nutritional compositions intended for adults with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to adults with an impaired function of the gastrointestinal tract comprising probiotic micro-organisms. The probiotic micro-organisms may be non-replicating, for example bioactive heat treated probiotic micro-organisms.

Abstract: The present invention relates to the field of nutrition for young children. In particular, the present invention relates to dry whole milk preparations comprising probiotic micro-organisms to be administered to young children older than 12 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Abstract: The present invention relates to a nutritional supplement compositions for breast-fed infants or pets which comprise at least one probiotic and at least one nutrient. The compositions are aimed at preserving exclusive breast feeding in infants. The compositions of the invention are also for use in improving the health of breast-fed infants. A method of preparing a nutritional supplement composition for breast-fed infants is also provided.

Abstract: The present invention relates to the field of nutrition. In particular, the present invention relates to a breakfast cereal composition comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.

Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.

Abstract: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicles for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention.